Text Size
54 studies found for:    Open Studies | "Wilms Tumor"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Unknown † Registry for Patients With Wilms' Tumor Suppressor Gene 1 (WT1) Mutation Associated Diseases
Conditions: Denys-Drash Syndrome;   Frasier Syndrome;   Nephrotic Syndrome;   Wilms Tumor
Intervention:
2 Recruiting Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Conditions: Adult Rhabdomyosarcoma;   Lung Metastases;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Wilms Tumor;   Stage V Wilms Tumor;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Radiation: intensity-modulated radiation therapy
3 Recruiting Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies
Conditions: Wilms' Tumor;   Aniridia
Interventions: Behavioral: Questionnaire;   Other: Blood specimen
4 Recruiting Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
Conditions: Childhood Hepatocellular Carcinoma;   Papillary Thyroid Cancer;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Childhood Liver Cancer;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Thyroid Cancer;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: Drug: sorafenib tosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
5 Unknown † National Wilm's Tumor Study Late Effects
Condition: Wilm's Tumor
Intervention: Other: none, screening only
6 Recruiting To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
Conditions: Sarcoma;   Neuroblastoma;   Wilms Tumor;   Leukemia;   Lymphoma;   Brain Tumors
Intervention: Drug: Marqibo
7 Unknown † Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor
Condition: Kidney Cancer
Interventions: Genetic: DNA methylation analysis;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: laboratory biomarker analysis
8 Unknown † Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor
Condition: Kidney Cancer
Interventions: Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy;   Radiation: radiation therapy
9 Recruiting Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Conditions: Kidney Cancer;   Nonneoplastic Condition
Interventions: Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
10 Recruiting Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms Tumor
Condition: Kidney Cancer
Interventions: Biological: dactinomycin;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Procedure: therapeutic conventional surgery;   Radiation: external beam radiation therapy
11 Not yet recruiting Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors
Conditions: Glioma;   Neuroectodermal Tumors, Primitive;   Wilms Tumor;   Rhabdomyosarcoma;   Sarcoma, Ewing;   Osteosarcoma;   Retinoblastoma
Interventions: Other: Control;   Drug: Metronomic Cyclophosphamide;   Drug: Thalomide
12 Recruiting Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
Conditions: Ewing's Sarcoma;   Osteosarcoma;   Astrocytoma;   Atypical Teratoid/Rhabdoid Tumor;   Ependymoma;   Germ Cell Tumor;   Glioma;   Medulloblastoma;   Rhabdoid Tumor;   Retinoblastoma;   Clear Cell Sarcoma;   Renal Cell Carcinoma;   Wilms Tumor;   Hepatoblastoma;   Neuroblastoma;   Rhabdomyosarcoma
Intervention: Drug: sirolimus
13 Recruiting iCAT for Recurrent/Refractory/HR Solid Tumors
Conditions: Pediatric Solid Tumor;   Sarcoma;   Neuroblastoma;   Wilms Tumor
Intervention:
14 Recruiting A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
Conditions: Ewing Sarcoma;   Gastrointestinal Tumor;   Germ Cell Tumor;   Hepatic Tumor;   Lymphoma;   Wilms Tumor;   Rhabdoid Tumor;   Clear Cell Carcinoma;   Renal Cell Carcinoma;   Melanoma;   Neuroblastoma;   Rhabdomyosarcoma;   Non-rhabdomyosarcoma
Interventions: Drug: alemtuzumab;   Drug: fludarabine;   Drug: sirolimus;   Drug: Busulfan;   Drug: melphalan;   Biological: stem cells
15 Recruiting Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms Tumor
Conditions: Kidney Cancer;   Metastatic Cancer
Interventions: Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy
16 Recruiting Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions
Conditions: WAGR Syndrome;   Wilm's Tumor;   Aniridia;   Urogenital Abnormalities;   Mental Retardation
Intervention:
17 Unknown † Gene Expression Profiles to Categorize Wilms Tumors
Condition: Kidney Cancer
Intervention: Genetic: microarray analysis
18 Recruiting Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Disseminated Neuroblastoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   High Risk Metastatic Gestational Trophoblastic Tumor;   Juvenile Myelomonocytic Leukemia;   Low Risk Metastatic Gestational Trophoblastic Tumor;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Plasma Cell Neoplasm;   Previously Treated Childhood Rhabdomyosarcoma;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Gestational Trophoblastic Tumor;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Neuroblastoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage II Ovarian Epithelial Cancer;   Stage II Ovarian Germ Cell Tumor;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Ovarian Epithelial Cancer;   Stage III Ovarian Germ Cell Tumor;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Breast Cancer;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: atorvastatin calcium;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation
19 Unknown † WT1 Peptid Vaccination in Carcinomas
Condition: WT1 Expressing Carcinoma
Intervention: Biological: WT1 126-134 peptide
20 Recruiting Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides
Conditions: Neuroblastoma;   Ewing's Sarcoma;   Wilm's Tumor;   Retinoblastoma;   Glioma
Intervention: Drug: racotumomab
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years